A post-hoc analysis of ENGAGE AF-TIMI 48 showed comparable efficacy, favorable safety, and better net clinical outcomes with edoxaban vs. warfarin in Asians, compared to non-Asians.
Real-world study suggests that rivaroxaban is associated with a lower risk of systemic embolism and stroke in NVAF patients taking ≥5 non-OAC medications. Polypharmacy did not affect risk of major bleeding.
A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.
In patients with heart failure, compared with sinus rhythm, atrial fibrillation was associated with worse long-term cardiovascular outcomes in HFmrEF and HFpEF, but not in chronic or acute HFrEF.
ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.
Continuous direct factor Xa inhibitor therapy with apixaban was a safe and effective anticoagulation alternative in patients at risk of stroke undergoing atrial fibrillation catheter ablation.
Longer total time spent in AF was associated with a higher risk of thromboembolism and ischemic stroke in adults with paroxysmal AF, who were not on anticoagulation, independent of known stroke risk factors.
Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.
ESC HF 2018 The second part of the Grand Debate on Drugs or interventions focused on the value of catheter ablation in comparison to drug for treatment of patients with both AF and HF.
In a retrospective analysis of a healthcare cost and utilization database, cannabis use was associated with a lower AF risk in hospitalized heart failure patients.
This conversation covers differences in efficacy and safety outcomes of treatment with DOACs or VKA, and how to decide what to give to whom and for how long, in light of the risk of antithrombotic and bleeding complications.